APA (7th ed.) Citation

Herrlinger, U., Brehmer, S., & Wick, W. (2019). Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): A randomised, open-label, phase 3 trial. The lancet, 393(10172), . https://doi.org/10.1016/S0140-6736(18)31791-4

Chicago Style (17th ed.) Citation

Herrlinger, Ulrich, Stefanie Brehmer, and Wolfgang Wick. "Lomustine-temozolomide Combination Therapy Versus Standard Temozolomide Therapy in Patients with Newly Diagnosed Glioblastoma with Methylated MGMT Promoter (CeTeG/NOA-09): A Randomised, Open-label, Phase 3 Trial." The Lancet 393, no. 10172 (2019). https://doi.org/10.1016/S0140-6736(18)31791-4.

MLA (9th ed.) Citation

Herrlinger, Ulrich, et al. "Lomustine-temozolomide Combination Therapy Versus Standard Temozolomide Therapy in Patients with Newly Diagnosed Glioblastoma with Methylated MGMT Promoter (CeTeG/NOA-09): A Randomised, Open-label, Phase 3 Trial." The Lancet, vol. 393, no. 10172, 2019, https://doi.org/10.1016/S0140-6736(18)31791-4.